Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that eflornithine 15% cream reduced unwanted facial hair growth more effectively than a placebo in women with hirsutism, but hair growth returned to pretreatment levels within 8 weeks of stopping treatment.

This review discusses treatments for frontal fibrosing alopecia and lichen planopilaris, noting that systemic 5-alpha reductase inhibitors are most effective for stabilization and potential hair regrowth, but reports no new clinical results.

This case report discusses the use of a prostaglandin analogue for treating eyebrow loss in a patient with frontal fibrosing alopecia, but provides no new clinical results.

This study found that three sessions of injectable platelet-rich fibrin (i-PRF+) significantly improved hair follicle density, hair volume, and thickness, as well as patient satisfaction in women with female pattern hair loss, with only minor self-limited adverse effects reported.

This article includes no new results; it discusses ongoing treatment approaches for frontal fibrosing alopecia and lichen planopilaris.

In this survey of dermatologists in India, most participants reported that nutritional deficiencies are common in alopecia patients and preferred using serum peptide formulations, rating them as "very good" or "good" for efficacy, with Folliserum receiving high marks for aesthetics.

This study found that finasteride-loaded nanostructured lipid carriers developed for topical application showed satisfactory size, stability, and prolonged drug release, suggesting potential for enhanced delivery in androgenic alopecia treatment.

In this study, O. forskahlii seed oil was found to promote hair growth in rats and exhibit anti-aging effects on human skin cells by enhancing fibroblast proliferation and inhibiting inflammation and enzyme activity, indicating potential for cosmetic use.

This report suggests a causal connection between hyaluronic acid filler injections and the development of xanthelasma, possibly through an inflammatory reaction that increases vascular permeability and LDL leakage.

This study reports two cases of follicular lichen planus, suggesting that GLPLS and LPP may be variants of this condition based on clinical and immunofluorescent findings.

This study found that topical tacalcitol improved roughness and scaling in erythromelanosis follicularis faciei et colli, although it was less effective for facial erythema.

In this study, applying FGF-2-containing dalteparin/protamine nanoparticles to the scalp was associated with a significant increase in hair diameter over six months among participants with thin hair.

Folicrex may help with hair growth and health but lacks clinical evidence.

This study reported that a novel ionic liquid delivery system combining ferulic acid and finasteride enhanced the solubility, skin permeation, and effectiveness in promoting hair regrowth in androgenetic alopecia mice, suggesting an improved topical treatment approach.

In this study, the researchers observed that treatment with intralesional and topical corticosteroids, finasteride, and minoxidil may stop the progression of frontal fibrosing alopecia in postmenopausal and premenopausal women.

This study found that home use of low-level light therapy reduced inflammation and symptoms like itching and burning in women with frontal fibrosing alopecia over six months.

This study observed that frontal fibrosing alopecia in postmenopausal women involves selective follicular inflammation, and finasteride treatment may slow disease progression, suggesting a potential androgen-related component.

This listing describes job openings at a hair restoration clinic that emphasizes quality, ethics, and natural results; no research findings are reported.

This study evaluates the compatibility of six active pharmaceutical ingredients, including finasteride and spironolactone, with TrichoFoam™, a foam vehicle used in personalized treatments for alopecia, though it does not report specific results.

This article discusses a novel multi-targeting approach to treating hair loss using standardized nutraceuticals but reports no new clinical results.

This systematic review of three randomized controlled trials found that topical eflornithine is an effective adjunctive therapy for reducing unwanted facial hair in women with hirsutism, with benefits lasting at least six months, although efficacy may diminish over time.

In this study, fibroblasts treated with the small molecule peficitinib were reprogrammed into dermal papilla cell-like cells capable of inducing hair growth, offering a new strategy for hair loss treatment.

This study found that PGF2alpha analogues and PGE2 stimulated hair follicle activity in mice, with PGF2alpha analogues also linked to potential side effects like poliosis when used as eye treatments.

In this study, researchers found that overexpression of LncRNA RP11-818O24.3 in hair follicle stem cells promotes their proliferation, self-renewal, and differentiation while inhibiting apoptosis through the FGF2-mediated PI3K/AKT signaling pathway, suggesting potential therapeutic applications for hair loss treatment.